Editoria e Media
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
This report provides a comprehensive analysis of the global market for biologic therapeutic drugs, segmented by product type (such as mAbs vaccines, and cell and gene therapies), source (mammalian, microbial, others), application (oncology, autoimmune, and infectious diseases), and region ( North America , Europe , Asia-Pacific , Middle East and Africa , and South America ). It explores key market trends, challenges, and ESG developments, and examines the emerging technologies shaping the industry. The report also includes a competitive landscape analysis with market share rankings and detailed profiles of leading companies.
This report is particularly relevant now due to the growing demand for innovative therapies and the rapid advances in regenerative medicine. Increased investments and intensified research activities are accelerating the development of biologic drugs, while a surge in product approvals is expanding treatment options in many medical fields. These factors are collectively driving significant growth in the biologics market, making timely insights into trends, challenges, and competitive dynamics more critical than ever.
Biologics are increasingly favored due to their high efficacy, targeted action, and ability to treat complex diseases like cancer and autoimmune disorders. Patients and healthcare providers are turning to these advanced therapies for better outcomes and fewer side effects.
The biopharma sector is seeing a surge in funding from pharmaceutical companies, investors, and governments. These investments support research, clinical trials, and manufacturing infrastructure, accelerating the development and availability of biologic drugs.
Collaborations between biotech firms and large pharmaceutical companies are common, enabling shared expertise, reduced costs, and faster product development. Licensing deals and joint ventures also help expand market reach and streamline commercialization.
Biologics are central to the shift toward personalized medicine, where treatments are tailored to individual genetic profiles. Advances in genomics and diagnostics enable more precise therapies, reducing trial-and-error in treatment
An aging global population is leading to a higher incidence of chronic diseases such as diabetes, cancer, and arthritis. Biologics offer effective long-term treatment options for these conditions, making them essential in managing the health needs of older adults.
Antibody Drugs: Technologies and Global Markets: This report provides reviews the global antibody drug market, focusing on monoclonal antibodies (mAbs) used in treating chronic diseases like cancer and autoimmune disorders. It covers market trends, regional analysis, and key companies. Forecasts extend to 2029, highlighting growth in therapeutic applications and technological advances.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/biologic-therapeutics-market-to-hit-794-5-billion-by-2029--302515197.html